Infections

233 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Infections
Treatment and conditionWhere it standsTrials
"Synchronised" arm (intervention) for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
4,4',4''-(4-PROPYL-(1H)-PYRAZOLE-1,3,5-TRIYL)TRISPHENOL for leptospirosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
4CMenB vaccine for gonorrheaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
9vHPV Vaccine for papillomavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
abrysvo + Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acoziborole for trypanosomiasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Acoziborole for trypanosomiasis, africanPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm D for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm F for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm H for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm J for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Adjuvant Dose Arm L for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen High Dose Arm A for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amezosvatein Antigen Low Dose Arm B for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amoxicillin for treponemal infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ansuvimab for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Artemether + Lumefantrine for malaria, vivaxPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Artemether + Lumefantrine + TAFENOQUINE for malaria, vivaxPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
artemether-lumefantrine for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
artemether-lumefantrine + Mosquirixs for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Artesunate for cytomegalovirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atovaquone-Proguanil for asymptomatic infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atovaquone-Proguanil for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Awake timed prone and repositioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD7760 for sepsisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD7760 for staphylococcal infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bacillus calmette-guerin live antigen, unspecified substrain for tuberculosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bedaquiline for tuberculosis, multidrug-resistantPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benznidazole for chagas diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Beyfortus for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezlotoxumab for clostridium infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blmz for tuberculosis, multidrug-resistantTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Blood and adrenaline for choleraPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood and adrenaline for shock, septicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
BPaLMZ Regimen for latent tuberculosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabamiquine for malaria, falciparumPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chlorhexidine for infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
coadministration for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Coartem® Baby for malariaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
COVID-19 vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for chickenpoxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CVI-VZV-001 for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for haemophilus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL®: DTaP for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL®: DTaP for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zosterPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dihydroartemisinin + Piperaquine tetraphosphate for malaria, vivaxPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dihydroartemisinin + Piperaquine tetraphosphate + TAFENOQUINE for malaria, vivaxPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dihydroartemisinin-Piperaquine (DP) for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for diphtheriaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for tetanusPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dolutegravir + Isoniazid + RIFAPENTINE for latent tuberculosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DTaP-IPV and ActHIB® for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DTaP-IPV and ActHIB® for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DTaP-IPV combined vaccine for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DTaP-IPV combined vaccine for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Efineptakin alfa for opportunistic infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
EG-MCV4 for meningococcal infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ervebo® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Etofenprox-treated lesu for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Factory-treated lesu for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Faecal bacteriotherapy (FBT) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbial Transplantation for clostridium infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fecal microbiota for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Fecal Microbiota Transplant for clostridium infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Fecal Microbiota Transplant (FMT) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal microbiota transplant (Promicrobioma) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbiota Transplantation (FMT) for clostridium infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbiota Transplantation (FMT) + ISOTONIC SODIUM CHLORIDE SOLUTION for clostridium infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Fecal microbiota transplantion (FMT) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Transplant for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Virome Transplantation for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fidaxomicin for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Flucytosine (5FC) for mycosesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Flucytosine (5FC) + Liposomal Amphotericin B (LAmB) for mycosesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fluvoxamine for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fmt for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)3
FMT (Fecal Microbiota Transplantation) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FMT-c Lactobacillus for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Formulation B for pneumococcal infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Formulation C for pneumococcal infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Formulation D for pneumococcal infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fosravuconazole + benznidazole for chagas diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fresh FMT for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Frozen-and-Thawed FMT for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Gepotidacin for gonorrheaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
GSK malaria vaccine 257049 Vaccine for malariaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Healthy donor stool for clostridium infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hemoperfusion for leptospirosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxychloroquine for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
hydroxychloroquine + azithromycin for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for adenoviridae infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IFN-γ positive selected T-cells for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Immulina for virus diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Inmazeb for hemorrhagic fever, ebolaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Isoniazid + RIFAPENTINE for latent tuberculosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Ivermectin for asymptomatic infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivermectin for communicable diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivermectin for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Landiolol for shock, septicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for cytomegalovirus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lb-dtk-mv for epstein-barr virus infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LBP-EC01 for escherichia coli infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LBP-EC01 0.01x IV Dose for escherichia coli infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LBP-EC01 0.1 x IV dose for escherichia coli infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LBP-EC01 IV Infusion Dose for escherichia coli infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Liposomal Amphotericin B (LAmB) for mycosesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Low Dose FMT Capsule DE for clostridium infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose experimental vaccine for herpes zosterPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 200 mg + PYRONARIDINE for asymptomatic infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 200 mg + PYRONARIDINE for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 330 mg + PYRONARIDINE for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 500 mg + M5717 660 mg + PYRONARIDINE for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 60 mg + PYRONARIDINE for asymptomatic infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 60 mg + PYRONARIDINE for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 660mg + PYRONARIDINE for asymptomatic infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M5717 660mg + PYRONARIDINE for malaria, falciparumPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine for tuberculosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Malaria Vaccine 257049 for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Malaria Vaccine 257049 + Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparumPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
MBK-01 for clostridium infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Meningococcal Group B Vaccine for gonorrheaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for tuberculosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Methylenblue for malariaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
METRONIDAZOLE + Vancomycin + Loperamide + FECAL MICROBIOTA for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Midodrine for sepsisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mosquirixs for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Moxifloxacin + rifapentine for tuberculosis, lymph nodePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
mRNA-1018-H5 for influenza in birdsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mtbvac for tuberculosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
N-Acetylcysteine (NAC) Treatment for tuberculosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nifurtimox for chagas diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Nirsevimab for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
pBI-11 (3 doses) for papillomavirus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEDIACEL® and Prevenar® for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PEDIACEL® and Prevenar® for haemophilus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PEDIACEL® and Prevenar® for pneumococcal infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PEDIACEL® and Prevenar® for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Penn Microbiome Therapy - 001 for clostridium infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Penn Microbiome Therapy - 001 + Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Pentacel®: DTaP-IPV/Hib combined for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pentacel®: DTaP-IPV/Hib combined for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Permethrin-treated lesu for malariaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Permethrin-treated lesu for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PG4 for pneumococcal infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for tuberculosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malariaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Posaconazole for chagas diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Povidone-iodine for surgical wound infectionPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Primaquine for malaria, vivaxPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Prone Position for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
prone positioning for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prone Positioning (PP) for coronavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pvs230D1-EPA/Matrix-M for malaria, vivaxTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pvs230D1-EPA/Matrix-M for parasitemiaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quabodepistat for tuberculosis, multidrug-resistantPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
R21 in Matrix- M adjuvant vaccine for malaria, falciparumPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
R21/Matrix-M - single vial formulation for malariaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
R21/Matrix-M - two vial formulation for malariaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
rabies vaccine for rabiesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
RBX2660 for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RBX2660 for communicable diseasesPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
RBX2660 (microbiota suspension) for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for herpes zosterPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebolaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
RSVPreF3 OA investigational vaccine for respiratory syncytial virus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
S-337395 for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Single high dose of liposomal amphotericin B for histoplasmosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Soaked lesu for malaria, falciparumTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Standardized kudzu for sexually transmitted diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sucrose for surgical wound infectionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tafenoquine for malaria, vivaxPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
Tafenoquine + chloroquine for malaria, vivaxPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tafenoquine succinate for malaria, vivaxPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for diphtheriaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for tetanusTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Telacebec + Rifampicine for leprosy, multibacillaryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Telacebec 300 mg for leprosy, multibacillaryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Telacebec 600 mg for leprosy, multibacillaryTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) for gonorrheaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml) for gonorrheaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tetanus-Diphtheria booster for papillomavirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Titrated weaning of vasopressin. for shock, septicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Topical ceftazidime and vancomycin for surgical wound infectionPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tradipitant for coronavirus infectionsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for sepsisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 high-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
UB-621 low-dose for herpes genitalisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Valganciclovir for cytomegalovirus infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vancomycin for clostridium infectionsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vasopressin for shock, septicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Venous Excess Ultrasound (VEXUS)-Guided Management for shock, septicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vi-Typhoid Conjugate Vaccine (Vi-TCV) for typhoid feverPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Viral Specific T-cells (VSTs) for virus diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VLA15 for lyme diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
VXA-G1.1-NN for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VXA-G2.4-NS for caliciviridae infectionsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wharton's jelly derived Mesenchymal stem cells. for coronavirus infectionsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for chikungunya feverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for dengueTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Wolbachia-infected Aedes aegypti for zika virus infectionTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Zabdeno® booster for hemorrhagic fever, ebolaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zelicapavir for respiratory syncytial virus infectionsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zoliflodacin for gonorrheaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2